We were delighted to catch up with Dr. Bart Westerman (VU Medical Center, Amsterdam UMC, Amsterdam, The Netherlands) to discuss his presentation entitled ‘An AI Model Can Help Predict Adverse Events From New Drug Combinations’, which was presented at AACR 2022, 8-13 April 2022.
Questions
- Why is it important to better predict the benefit-risk profile of potential cancer treatments, particularly combination therapy? (0:21)
- What methodology did you use to examine whether a machine learning approach can predict adverse drug reactions from drug combinations? (1:46)
- How accurate was the model in determining individual treatment adverse event profiles? (3:40)
- Are there any potential limitations to this approach? (4:45)
- What further work needs to be conducted to validate the use of the machine learning approach for clinical practice? (5:31)
Disclosures: Bart Westerman discloses receiving Dutch Cancer Society grants KWF-4874 and KWF-11038, Brain Tumour Charity Grant 488097 and APCA-PoC-2017; a relationship with Health Holland that includes: funding grants; receiving a public-private partnership fund from Health Holland on a peer-reviewed project where the company Medstone is the private party and contributor to the project.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the AACR annual meeting 2022.
